Allergan sales fueled by Botox, eye-care strength; Crohn's market to see 'modest' growth; Mallinckrodt eyes $2.3B in fiscal 2014 sales;

@FiercePharma: Pharma giants arm-twist U.S. government for IP action in India. Story | Follow @FiercePharma

@TracyStaton AstraZeneca, on the other hand, saw Q4/full year 'in line with our expectations,' which means generics are still hitting hard. | Follow @TracyStaton

@EricPFierce: The FDA prescription for fighting counterfeit drugs includes targeting the docs who buy them. More | Follow @EricPFierce

> Allergan ($AGN) posted a 14% increase in fourth-quarter revenue, fueled by double-digit boosts to Botox and eye-care drugs. Report

> The Crohn's disease market is expected to grow modestly through 2022, to $4.2 billion, which makes for a compound annual growth rate of 2.8%, GlobalData finds. Report

> Mallinckrodt ($MNK) reported quarterly profits of $45.6 million, more than double last year's result, and forecast fiscal 2014 sales of up to $2.3 billion. Report

> Merck KGaA extended its $2.6 billion offer for AZ Electronic Materials, which would augment its liquid crystals business. Report

> Twenty-five people, including doctors, were rounded up by New York City law enforcement and charged in a scheme to sell painkillers on the black market. Report

Medical Device News

@FierceMedDev: A judge said J&J wrongly eliminated thousands of key vaginal mesh docs. More | Follow @FierceMedDev

@MarkHFierce: Xerox is testing some really interesting patient monitoring tech. Yes, Xerox. Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceDrugDelivery's special report: The top drug delivery partnerships of 2013. Report | Follow @MichaelGFierce

@EmilyWFierce: GE sells off Breas Medical to PBM Capital. Release | Follow @EmilyWFierce

> Analysts: Rivals may seek to beat Smith & Nephew's $1.7B ArthroCare offer. Story

> St. Jude puts the Nanostim leadless pacemaker in its first U.S. patient. More

Biotech News

@FierceBiotech: With biotech stocks sizzling, drug developers are bringing home the bacon. Story | Follow @FierceBiotech

@JohnCFierce: AstraZeneca adds 550 jobs to the chopping block as profits shrivel. News | Follow @JohnCFierce

@DamianFierce: Today in biotech IPOs: Revance, Eleven Biotherapeutics and Egalet raised a combined $196M in their debuts. Read | Follow @DamianFierce

@EmilyMFierce: Global cancer rates expected to hit 22 million new cases per year by 2030, according to WHO. Story via CBS News | Follow @EmilyMFierce

> U.K. biotech Circassia eyes $285M in a London IPO. Piece

> AstraZeneca quietly sweeps out some notable mid-stage drug programs. More

Pharma Manufacturing News

> FDA Commissioner Hamburg heads for India to talk about quality manufacturing. News

> As Ranbaxy's plant problems mount, so do its losses. More

> BMS plots major job cuts at plants in France. Story

> AbbVie picks Singapore for a $320M production facility. Article

> 7 Ohio docs pony up $2.6M for buying foreign-made cancer drugs. Piece

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Item

Vaccines News

> GSK is refusing to write off its cancer vaccine despite last year's PhIII flop. Article

> Circassia to test U.K. investors' appetite for risk with a $285M IPO. More

> Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls. Story

> Study: Merck's and GSK's HPV vaccines don't encourage risky sex. Piece

> CDC finds rare cases of nurses injecting GSK's and Merck's oral rotavirus vaccines. News

NIH leaders view HIV vaccine as essential to ending AIDS pandemic. Item

And Finally... Worries about diabetes risk? Eat some yogurt, a study suggests. Report

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.